PTCT लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

खरीदें 118277 min ago

@ $25.11

जारी किया गया: 15 Feb 2024 @ 02:11

वापसी: 31.26%

पिछला सिग्नल: Feb 14 - 02:13

पिछला सिग्नल: बेचें

वापसी: 3.95 %

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 01:30):

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders...

Stats
आज की मात्रा	460 567
औसत मात्रा	910 681
बाजार मूल्य	2.52B
EPS	$0 ( 2024-04-25 )
अगली कमाई की तारीख	( $-1.250 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.94
ATR14	$0.0300 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Klein Matthew B.	Sell	3 361	Common Stock
2024-04-17	Pauwels Eric	Sell	787	Common Stock
2024-04-17	Klein Matthew B.	Sell	1 307	Common Stock
2024-04-02	Golden Lee Scott	Sell	526	Common Stock
2024-02-15	Utter Christine Marie	Buy	2 900	Common Stock

INSIDER POWER
73.44
Last 98 transactions
Buy: 1 039 114 \| Sell: 204 439

मात्रा सहसंबंध

लंबा: 0.25 (neutral)

छोटा: 0.83 (strong)

Signal:(60.339) Same movement expected

PTC Therapeutics Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
MOSY	0.894
ATCX	0.831
IKNX	0.824
SPKE	0.821
ICON	0.82
SYKE	0.811
APOP	0.811
NTES	0.807
APR	0.805
UBX	0.804

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

PTC Therapeutics Inc सहसंबंध - मुद्रा/वस्त्र

0.37
( neutral )

0.32
( neutral )

0.00
( neutral )

0.23
( neutral )

0.40
( neutral )

-0.12
( neutral )

PTC Therapeutics Inc वित्तीय

Annual	2023
राजस्व:	$937.82M
सकल लाभ:	$649.70M (69.28 %)
EPS:	$-8.37

FY	2023
राजस्व:	$937.82M
सकल लाभ:	$649.70M (69.28 %)
EPS:	$-8.37

FY	2022
राजस्व:	$698.80M
सकल लाभ:	$654.12M (93.61 %)
EPS:	$-7.79

FY	2021
राजस्व:	$538.59M
सकल लाभ:	$506.27M (94.00 %)
EPS:	$-7.26

Financial Reports:

No articles found.

PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.